Bioprosthetic Valve Failure After Transcatheter Aortic Valve Replacement.

Authors

Antonin Trimaille, Pedro Cepas-Guillén, Marina Urena, Alberto Alperi, Gabriela Veiga-Fernandez, Luis Nombela-Franco, Victoria Vilalta, Maria Del Trigo, Antonio J Muñoz-García, Giovanni Esposito, Vincent Auffret, David Del Val, Vicenç Serra, Jorge Nuche, Lluis Asmarats, Ander Regueiro, Adrien Carmona, Quentin Fisher, Pablo Avanzas, Víctor Fradejas-Sastre, Ivan Sanchez, Michele Trichilo, Juan Francisco Oteo, Anna Franzone, Maxime Nolf, Fernando Alfonso, Pedro Díaz Pockels, Rocío Rodríguez-Santolino, Dabit Arzamendi, Eduardo Flores-Umanzor, Olivier Morel, Marisa Avvedimento, Josep Rodés-Cabau

Published in

Circulation. Cardiovascular interventions. Pages e016892. Aug 24, 2026. Epub Aug 24, 2026.

Abstract

Data on the long-term incidence and clinical impact of bioprosthetic valve failure (BVF) after transcatheter aortic valve replacement remain limited. This study aimed to assess the incidence, predictors, and clinical impact of BVF following transcatheter aortic valve replacement.
We analyzed data from an international, multicenter registry including consecutive patients undergoing transcatheter aortic valve replacement at 13 centers. The primary outcome was BVF according to Valve Academic Research Consortium-3 criteria. The cumulative incidence of BVF was estimated using a competing-risk approach. The association between BVF and clinical outcomes was assessed using competing-risk models with BVF as a time-dependent covariate.
Among 7501 patients, BVF occurred in 380 (5.1%) patients over a median follow-up of 4 (interquartile range, 2-5) years. The cumulative incidence of BVF increased over time, reaching 1.4% at 1 year, 4.6% at 5 years, and 8.3% at 10 years. Independent predictors of BVF included younger age, smoking, balloon-expandable valve, prosthesis size <26 mm, valve-in-valve procedure, mean gradient at discharge ≥15 mm Hg, moderate or severe aortic regurgitation at discharge, and early hemodynamic valve deterioration. BVF was independently associated with an increased risk of all-cause mortality (adjusted hazard ratio, 1.72 [95% CI, 1.47-2.01]; P<0.001), cardiovascular mortality (adjusted hazard ratio, 3.23 [95% CI, 2.73-3.82]; P<0.001), stroke (adjusted hazard ratio, 2.08 [95% CI, 1.02-4.23]; P=0.043), and heart failure hospitalization (adjusted hazard ratio, 1.43 [95% CI, 1.03-1.98]; P=0.032). Consistent findings were observed in different sensitivity analyses.
BVF is a clinically relevant event associated with adverse long-term outcomes. These findings support the implementation of tailored surveillance and preventive strategies to mitigate BVF-related risk.

PMID:
42635326
Bibliographic data and abstract were imported from PubMed on 24 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.